comparemela.com

Latest Breaking News On - Institutional investors weigh in on terns pharmaceuticals - Page 1 : comparemela.com

Terns Pharmaceuticals (NASDAQ:TERN) Earns Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $5.50 target price on the stock. HC Wainwright also issued estimates for Terns Pharmaceuticals’ Q2 2024 earnings at ($0.33) EPS, FY2024 earnings at […]

Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Outperform Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research note released on Tuesday morning, Benzinga reports. JMP Securities currently has a $15.00 target price on the stock. Other analysts also recently issued research reports about the stock. BMO Capital Markets increased their target price on […]

Brokerages Set Terns Pharmaceuticals, Inc (NASDAQ:TERN) Price Target at $14 94

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) have been given an average rating of “Moderate Buy” by the eight analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month […]

Brokerages Set Terns Pharmaceuticals, Inc (NASDAQ:TERN) Target Price at $14 94

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The […]

Terns Pharmaceuticals (NASDAQ:TERN) Rating Reiterated by JMP Securities

JMP Securities reissued their market outperform rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $17.00 price objective on the stock. Several other research analysts have also recently issued reports on TERN. HC Wainwright decreased their price objective on […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.